Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
ZyVersa Therapeutics Inc is a clinical stage specialty biopharmaceutical company that leverages advanced proprietary technologies to develop and commercialize first-in-class prescription drugs. The company's focus is on restoring health and improving quality of life for patients with high unmet medi... ZyVersa Therapeutics Inc is a clinical stage specialty biopharmaceutical company that leverages advanced proprietary technologies to develop and commercialize first-in-class prescription drugs. The company's focus is on restoring health and improving quality of life for patients with high unmet medical needs, with emphasis on inflammatory and renal diseases. Mehr anzeigen
During obesity, inflammasome-driven inflammation results in significant loss of pancreatic islet beta cell mass, severely impairing the insulin secreting capacity of the remaining beta...
Obesity, due to its associated chronic, systemic inflammation, increases the risk for metabolic diseases, atherosclerosis, various malignant tumors, and numerous immune-mediated disorders.With...
Recent evidence links obesity-driven inflammation to diminished brain health and neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseasesThe newly published data show that obesity...
Lead indication for ZyVersa’s Inflammasome ASC Inhibitor IC 100 is obesity with metabolic complications. WESTON, Fla., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA...
WESTON, Fla., Oct. 15, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...
New Scientific Advisory Board (SAB) comprised of five leading experts in the areas of obesity and metabolic diseases, and four leading inflammasome experts and inventors of IC 100 from University...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.4199 | 20.0909090909 | 2.09 | 3.37 | 1.82 | 41706 | 1.94456239 | CS |
| 4 | 0.2399 | 10.5682819383 | 2.27 | 3.37 | 1.82 | 286789 | 2.21468911 | CS |
| 12 | -0.3201 | -11.3109540636 | 2.83 | 4.02 | 1.82 | 154503 | 2.42079379 | CS |
| 26 | -3.2901 | -56.725862069 | 5.8 | 6.6855 | 1.82 | 145653 | 3.62858039 | CS |
| 52 | -27.3101 | -91.5831656606 | 29.82 | 42.385 | 1.82 | 1363668 | 15.55908095 | CS |
| 156 | -4897.4901 | -99.948777551 | 4900 | 5232.5 | 1.82 | 1966641 | 86.28927736 | CS |
| 260 | -4897.4901 | -99.948777551 | 4900 | 5232.5 | 1.82 | 1966641 | 86.28927736 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
